Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis.
BACKGROUND
The use of antiemetics for children with vomiting is one of the most controversial decisions in the treatment of gastroenteritis in developed countries. Ondansetron, a selective serotonin receptor antagonist, has been found to be effective in improving the success of oral rehydration therapy. However, North American and European clinical practice guidelines continue to recommend against its use, stating that evidence of cost savings would be required to support ondansetron administration. Thus, an economic analysis of the emergency department administration of ondansetron was conducted. The primary objective was to conduct a cost analysis of the routine administration of ondansetron in both the United States and Canada.


RESULTS
A cost analysis evaluated oral ondansetron administration to children presenting to emergency departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer's perspective in both the US and Canada. A decision tree was developed that incorporated the frequency of vomiting, intravenous insertion, hospitalization, and emergency department revisits. Estimates of the monetary costs associated with ondansetron use, intravenous rehydration, and hospitalization were derived from administrative databases or emergency department use. The economic burden in children administered ondansetron plus oral rehydration therapy was compared to those not administered ondansetron employing deterministic and probabilistic simulations. We estimated the costs or savings to society and health care payers associated with the routine administration of ondansetron. Sensitivity analyses considered variations in costs, treatment effects, and exchange rates. In the US the administration of ondansetron to eligible children would prevent approximately 29,246 intravenous insertions and 7,220 hospitalizations annually. At the current average wholesale price, its routine administration to eligible children would annually save society US$65.6 million (US$49.1-US$81.1) and health care payers US$61.1 million (US$46.2-US$76.3). In Canada the administration of ondansetron to eligible children would prevent 4,065 intravenous insertions and 1,003 hospitalizations annually. Its routine administration would annually save society CDN$1.72 million (CDN$1.15-CDN$1.89) and the health care system CDN$1.18 million (CDN$0.88-CDN$1.41).


CONCLUSIONS
In countries where intravenous rehydration is often employed, the emergency department administration of oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis results in significant monetary savings compared to a no-ondansetron policy. Please see later in the article for the Editors' Summary.
Division of Pediatric Emergency Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada. stephen.freedman@sickkids.ca
Stephen B
SB
Freedman
Michael J
MJ
Steiner
Kevin J
KJ
Chan
D000284:Administration, Oral; D000465:Algorithms; D000932:Antiemetics / Q000008:administration & dosage / Q000191:economics; D002170:Canada; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004632:Emergency Medical Services / Q000379:methods; D004636:Emergency Service, Hospital / Q000191:economics*; D005440:Fluid Therapy / Q000191:economics; D005759:Gastroenteritis / Q000150:complications / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D017048:Health Care Costs; D006801:Humans; D017294:Ondansetron / Q000008:administration & dosage* / Q000191:economics*; D014481:United States; D014839:Vomiting / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology
D000932:Antiemetics; D017294:Ondansetron